As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Eli Lilly & Co. broadened its effort to crack down on fake and off-brand versions of hit obesity drug Zepbound, saying it has filed more lawsuits against companies selling compounded versions of ...

Last November, Eli Lilly received FDA approval for obesity drug Zepbound. In the second quarter, Zepbound generated over $1.2 billion in revenue! Investor Alert: Our 10 best stocks to buy right ...

Eli Lilly & Co. broadened its effort to crack down on fake and off-brand versions of hit obesity drug Zepbound, saying it has filed more lawsuits against companies selling compounded versions of ...